| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| Ab170540-100μg |
100μg |
期货  |
| |
| Ab170540-1mg |
1mg |
现货 |
| |
| Ab170540-5mg |
5mg |
现货 |
| |
| Ab170540-10mg |
10mg |
现货 |
|
| 产品名称 | Farletuzumab (anti-FOLR1), 叶酸受体 alpha 抑制剂 |
|---|---|
| 别名 | 法瑞珠单抗（抗 FOLR1） |
| 英文别名 | Adult folate-binding protein | FBP | Folate receptor 1 | Folate receptor, adult | FR-alpha | KB cells FBP | Ovarian tumor-associated antigen MOv18 |
| 规格或纯度 | 无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA |
| 宿主种属 | 人(Human) |
| 特异性 | FOLR1 |
| 种属反应性 | 人(Human) |
| 偶联 | Unconjugated |
| 作用类型 | 抑制剂 |
| 作用机制 | 叶酸受体 alpha 抑制剂 |
| 克隆类型 | 重组抗体 |
|---|---|
| Format | Whole IgG |
| 亚型 | Human IgG1 |
| 轻链亚型 | kappa |
| SDS-PAGE | 26.9 kDa (Light Chain) & 52.2 kDa (Heavy Chain), under reducing conditions; 181.9 kDa, under non-reducing conditions. |
| 纯化方法 | Protein A purified |
| 纯度 | >95% |
| 物理外观 | Liquid |
| 储存缓冲液 | Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0 |
| 防腐剂 | No |
| 浓度 | 见COA |
| 储存温度 | -80℃储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。 |
| CAS编号和信息 | 896723-44-7 |
| 分子类型 | 抗体 |
Farletuzumab (anti-FOLR1) (Ab170540) - Flow Cytometry
Flow Cytometry analysis of HeLa cells labelling FOLR1 (red) with Farletuzumab (anti-FOLR1) (Ab170540). Goat Anti-Human IgG (FITC) (Ab175834) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Farletuzumab (anti-FOLR1) (Ab170540) - SEC
The purity of Farletuzumab (anti-FOLR1) (Ab170540) is more than 95% verified by HPLC.
Farletuzumab (anti-FOLR1) (Ab170540) - ELISA
Immobilized huFOLR1 at 2 μg/mL can bind Farletuzumab (anti-FOLR1) (Ab170540) with the EC₅₀ of 18.95 ng/mL.
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！
| 批号(Lot Number) | 证书类型 | 日期 | 货号 |
|---|---|---|---|
 ZJ23F0800915 |
分析证书 | 25-05-23 | Ab170540 |
| ZJ23F0800916 |
分析证书 | 25-05-23 | Ab170540 |
| ZJ23F0800917 |
分析证书 | 25-05-23 | Ab170540 |
¥639.90
| 1. Campbell IG, Jones TA, Foulkes WD, Trowsdale J. (1991) Folate-binding protein is a marker for ovarian cancer.. Cancer Res, 51 (19): (5329-38). [PMID:1717147] [10.1021/op500134e] |
| 2. Ab O, Whiteman KR, Bartle LM, Sun X, Singh R, Tavares D, LaBelle A, Payne G, Lutz RJ, Pinkas J et al.. (2015) IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.. Mol Cancer Ther, 14 (7): (1605-13). [PMID:25904506] [10.1021/op500134e] |
| 3. Yijun Deng,Yiqiang Wang,Christina Cherian,Zhanjun Hou,Steven A Buck,Larry H Matherly,Aleem Gangjee. (2008-08-06) Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.. Journal of medicinal chemistry, 51 ((16)): (5052-5063). [PMID:18680275] |
| 4. Deng Y, Zhou X, Kugel Desmoulin S, Wu J, Cherian C, Hou Z, Matherly LH, Gangjee A.. (2009) Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.. J Med Chem, 52 (9): (2940-2951). [PMID:19371039] [10.1021/jm8011323] |
| 5. Wang L, Cherian C, Desmoulin SK, Polin L, Deng Y, Wu J, Hou Z, White K, Kushner J, Matherly LH, Gangjee A.. (2010) Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.. J Med Chem, 53 (3): (1306-1318). [PMID:20085328] [10.1021/jm9015729] |
| 6. Wang L, Desmoulin SK, Cherian C, Polin L, White K, Kushner J, Fulterer A, Chang MH, Mitchell-Ryan S, Stout M, Romero MF, Hou Z, Matherly LH, Gangjee A.. (2011) Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-glycinamide ribonucleotide formyltransferase.. J Med Chem, 54 (20): (7150-7164). [PMID:21879757] [10.1021/jm200739e] |
| 7. Wang L, Cherian C, Kugel Desmoulin S, Mitchell-Ryan S, Hou Z, Matherly LH, Gangjee A.. (2012) Synthesis and biological activity of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl regioisomers as inhibitors of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier.. J Med Chem, 55 (4): (1758-1770). [PMID:22243528] [10.1021/jm201688n] |
| 8. Wang Y, Cherian C, Orr S, Mitchell-Ryan S, Hou Z, Raghavan S, Matherly LH, Gangjee A.. (2013) Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.. J Med Chem, 56 (21): (8684-8695). [PMID:24111942] [10.1021/jm401139z] |
| 9. Mitchell-Ryan S, Wang Y, Raghavan S, Ravindra MP, Hales E, Orr S, Cherian C, Hou Z, Matherly LH, Gangjee A.. (2013) Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implications of inhibiting 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase to ampk activation and antitumor activity.. J Med Chem, 56 (24): (10016-10032). [PMID:24256410] [10.1021/jm401328u] |
| 10. Golani LK, George C, Zhao S, Raghavan S, Orr S, Wallace A, Wilson MR, Hou Z, Matherly LH, Gangjee A.. (2014) Structure-activity profiles of novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolates with modified amino acids for cellular uptake by folate receptors α and β and the proton-coupled folate transporter.. J Med Chem, 57 (19): (8152-8166). [PMID:25234128] [10.1021/jm501113m] |
| 11. Wang Y, Mitchell-Ryan S, Raghavan S, George C, Orr S, Hou Z, Matherly LH, Gangjee A.. (2015) Novel 5-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase and as potential antitumor agents.. J Med Chem, 58 (3): (1479-1493). [PMID:25602637] [10.1021/jm501787c] |
| 12. Wang L, Wallace A, Raghavan S, Deis SM, Wilson MR, Yang S, Polin L, White K, Kushner J, Orr S, George C, O'Connor C, Hou Z, Mitchell-Ryan S, Dann CE, Matherly LH, Gangjee A.. (2015) 6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor α and the Proton-Coupled Folate Transporter in Human Tumors.. J Med Chem, 58 (17): (6938-6959). [PMID:26317331] [10.1021/acs.jmedchem.5b00801] |
| 13. Ravindra M, Wallace-Povirk A, Karim MA, Wilson MR, O'Connor C, White K, Kushner J, Polin L, George C, Hou Z, Matherly LH, Gangjee A.. (2018) Tumor Targeting with Novel Pyridyl 6-Substituted Pyrrolo[2,3- d]Pyrimidine Antifolates via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of De Novo Purine Nucleotide Biosynthesis.. J Med Chem, 61 (5): (2027-2040). [PMID:29425443] [10.1021/acs.jmedchem.7b01708] |
| 14. Ravindra M, Wilson MR, Tong N, O'Connor C, Karim M, Polin L, Wallace-Povirk A, White K, Kushner J, Hou Z, Matherly LH, Gangjee A.. (2018) Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.. J Med Chem, 61 (9): (4228-4248). [PMID:29701475] [10.1021/acs.jmedchem.8b00408] |
| 15. Golani LK, Wallace-Povirk A, Deis SM, Wong J, Ke J, Gu X, Raghavan S, Wilson MR, Li X, Polin L, de Waal PW, White K, Kushner J, O'Connor C, Hou Z, Xu HE, Melcher K, Dann CE, Matherly LH, Gangjee A.. (2016) Tumor Targeting with Novel 6-Substituted Pyrrolo [2,3-d] Pyrimidine Antifolates with Heteroatom Bridge Substitutions via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.. J Med Chem, 59 (17): (7856-7876). [PMID:27458733] [10.1021/acs.jmedchem.6b00594] |
| 16. Sadasivan, E E, Cedeno, M M and Rothenberg, S P SP.. (1992) Genomic organization of the gene and a related pseudogene for a human folate binding protein.. Biochimica et biophysica acta, (7): [PMID:1581364] |
| 17. Coney, L R LR and 6 more authors.. (1991) Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein.. Cancer research, (15): [PMID:1840502] |
| 18. Lacey, S W SW, Sanders, J M JM, Rothberg, K G KG, Anderson, R G RG and Kamen, B A BA.. (1989) Complementary DNA for the folate binding protein correctly predicts anchoring to the membrane by glycosyl-phosphatidylinositol.. The Journal of clinical investigation, [PMID:2527252] |
| 19. Sadasivan, E E and Rothenberg, S P SP.. (1989) The complete amino acid sequence of a human folate binding protein from KB cells determined from the cDNA.. The Journal of biological chemistry, (5): [PMID:2538429] |
| 20. and Elwood, P C PC.. (1989) Molecular cloning and characterization of the human folate-binding protein cDNA from placenta and malignant tissue culture (KB) cells.. The Journal of biological chemistry, (5): [PMID:2768245] |
| 21. Luhrs, C A CA and 7 more authors.. (1987) Purified membrane and soluble folate binding proteins from cultured KB cells have similar amino acid compositions and molecular weights but differ in fatty acid acylation.. Proceedings of the National Academy of Sciences of the United States of America, [PMID:3476960] |
| 22. Yan, W W and Ratnam, M M.. (1995) Preferred sites of glycosylphosphatidylinositol modification in folate receptors and constraints in the primary structure of the hydrophobic portion of the signal.. Biochemistry, (7): [PMID:7578066] |
| 23. Orr, R B RB and Kamen, B A BA.. (1994) UMSCC38 cells amplified at 11q13 for the folate receptor synthesize a mutant nonfunctional folate receptor.. Cancer research, (15): [PMID:8033114] |
| 24. Elwood, P C PC and 6 more authors.. (1997) The divergent 5' termini of the alpha human folate receptor (hFR) mRNAs originate from two tissue-specific promoters and alternative splicing: characterization of the alpha hFR gene structure.. Biochemistry, (11): [PMID:9063895] |
| 25. Chancy, C D CD and 8 more authors.. (2000) Expression and differential polarization of the reduced-folate transporter-1 and the folate receptor alpha in mammalian retinal pigment epithelium.. The Journal of biological chemistry, (7): [PMID:10787414] |
| 26. and Kalli, Kimberly R KR.. (2007) MORAb-003, a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer.. Current opinion in investigational drugs (London, England : 2000), [PMID:18058577] |
| 27. Zhao, Rongbao R and 5 more authors.. (2009) A role for the proton-coupled folate transporter (PCFT-SLC46A1) in folate receptor-mediated endocytosis.. The Journal of biological chemistry, (13): [PMID:19074442] |
| 28. Steinfeld, Robert R and 8 more authors.. (2009) Folate receptor alpha defect causes cerebral folate transport deficiency: a treatable neurodegenerative disorder associated with disturbed myelin metabolism.. American journal of human genetics, [PMID:19732866] |
| 29. Chen, Chen C and 8 more authors.. (2013) Structural basis for molecular recognition of folic acid by folate receptors.. Nature, (22): [PMID:23851396] |
| 30. Shum, Cheuk Fan and 7 more authors.. (2016) Novel Use of Folate-Targeted Intraoperative Fluorescence, OTL38, in Robot-Assisted Laparoscopic Partial Nephrectomy: Report of the First Three Cases.. Journal of endourology case reports, [PMID:27868096] |
| 31. Randall, Leslie M LM, Wenham, Robert M RM, Low, Philip S PS, Dowdy, Sean C SC and Tanyi, Janos L JL.. (2019) A phase II, multicenter, open-label trial of OTL38 injection for the intra-operative imaging of folate receptor-alpha positive ovarian cancer.. Gynecologic oncology, (27): [PMID:31362825] |
首页
400-620-6333
